A blood test for detecting cancer early being developed by the diagnostics firm Grail failed to meet its main goal in a giant study being conducted with England’s National Health Service, the company said Thursday.
Grail’s test has been the standard bearer for new technologies that promise a blood test can be used to detect many different types of cancer early and eventually even to indicate to scientists where in the body to look for tumors. The company already sells its test, called Galleri, for a list price of $1,000, although it is not yet approved by the Food and Drug Administration. Grail said Thursday it sold 185,000 tests in 2025, generating $136.8 million.
The company’s shares were down 47% in after-hours trading.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/02/19/grail-cancer-test-galleri-results/)
